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Abstract
Background: Available evidence suggests that the regulation of telomerase activity primarily
depends on the transcriptional control of the human telomerase reverse transcriptase (hTERT)
gene. Although several activators and repressors of hTERT gene transcription have been identified,
the exact mechanism by which hTERT transcription is repressed in normal cells and activated in
cancer cells remains largely unknown. In an attempt to identify possible novel mechanisms involved
in the regulation of hTERT transcription, the present study examined the role of Receptor Ck, a
cell surface receptor specific for cholesterol, in the transcription of hTERT gene in normal human
peripheral blood mononuclear cells.
Results:  Activated Receptor Ck was found to down-regulate hTERT mRNA expression by
repressing the transcription of c-myc gene. Receptor Ck-dependent signaling was also found to
down-regulate the mRNA expression of the gene coding for the ligand inducible transcription
factor, peroxisome proliferator-activated receptor γ (PPARγ). The ligand activation of PPARγ
resulted in the down-regulation of c-myc and hTERT mRNA expression. By using specific activator
and inhibitor of protein kinase C (PKC), it was demonstrated that Receptor Ck dependent down-
regulation of hTERT gene transcription involved inhibition of PKC. In addition, 25-
hydroxycholesterol was found to contribute to the transcriptional regulation of hTERT gene.
Conclusion: Taken together, the findings of this study present evidence for a molecular link
between cholesterol-activated Receptor Ck and hTERT transcription, and provide new insights into
the regulation of hTERT expression in normal human peripheral blood mononuclear cells.
Background
Telomeres are specialized DNA-protein complexes that
serve as protective caps of linear eukaryotic chromosomal
ends and are essential for chromosomal stability [1]. The
replication of telomeres during cell division poses a spe-
cial problem for the cells because the conventional DNA
polymerases are unable to completely replicate the chro-
mosome ends. Most eukaryotic cells employ the enzyme
telomerase for the maintenance of telomeres. Telomerase
is a RNA-dependent DNA polymerase that synthesizes tel-
omeric DNA sequences and almost universally provides
the molecular basis for unlimited proliferative potential.
The telomerase activity has been found to be absent in
most normal somatic cells but present in over 90% of can-
cerous cells and in vitro immortalized cells [2,3]. Telom-
erase is also expressed in germ line cells and in a small
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number of normal somatic cells that possess high turno-
ver capability, such as, haematopoietic stem cells, periph-
eral blood lymphocytes, skin keratinocytes, intestinal
crypt cells etc. [4]. Due to the absence of telomerase in
most normal somatic cells, telomeres in these cells,
shorten with progressive cell division in vitro and with
increased age in vivo [5,6]. This telomere shortening has
been proposed to act as a mitotic clock, which counts the
number of divisions undergone by a cell and triggers cel-
lular senescence at a critically short telomere length. The
maintenance of telomere length by telomerase is thus
essential for long-term cell proliferation and cell immor-
talization. The mechanisms involved in the regulation of
telomerase activity are of special interest since the modu-
lation of telomerase activity can be used to alter cellular
life span and thus, can be exploited in anti-cancer and
anti-ageing therapies.
The human telomerase consists of two essential compo-
nents: (i) the human telomerase RNA component (hTR or
hTERC) and (ii) the catalytic component, known as the
human telomerase reverse transcriptase (hTERT) [7]. Sev-
eral other protein subunits associate with these core com-
ponents to form the telomerase holoenzyme that
synthesizes telomeric DNA [7]. Among the multiple com-
ponents of human telomerase, only the catalytic subunit,
hTERT seems to be the key determinant of telomerase
activity. While the expression of hTERT is repressed in nor-
mal somatic cells (telomerase negative) and is upregu-
lated in immortal cells (telomerase positive), the other
components of telomerase holoenzyme are usually
expressed ubiquitously in both telomerase positive and
telomerase negative cells [7]. Although various steps at
post-transcriptional and post-translational levels have
been found to modulate telomerase activity, substantial
experimental data have established that the transcrip-
tional control of hTERT gene is the major contributor to
the regulation of telomerase activity in most cell types [7].
Binding sites for several transcription factors have been
identified on the promoter of hTERT gene. Transcription
factors such as c-myc, Sp1, nuclear factor-κB (NF-κB) and
upstream stimulatory factors (USF) have been shown to
upregulate hTERT transcription whereas transcription fac-
tors like Mad1, Wilms' tumor 1 (WT1) tumor suppressor
protein, E2F, p53 and myeloid cell-specific zinc finger
protein-2 (MZF-2) have been found to down-regulate
hTERT transcription [7-9]. Bcl-2, the oncoprotein
involved in the inhibition of cellular apoptosis has also
been reported to modulate telomerase activity [10,11].
Several studies have implicated sex steroid hormones
(estrogen, progesterone and androgens) in the regulation
of hTERT transcription [7]. Some human chromosomes
(chromosome 3, 4, 6, 7, 10 and 17) have been found to
potentially contain transcriptional repressors of hTERT
[12]. The hTERT gene is also a target site for viruses fre-
quently associated with human cancers, such as human
papillomavirus and hepatitis B virus [12]. Further, some
studies suggest that methylation of the promoter of hTERT
gene may contribute to the repression of hTERT gene tran-
scription in some cell types [12]. There is also evidence to
suggest that chromatin remodeling by various transcrip-
tion factors may be involved in the regulation of hTERT
gene transcription [12]. Although the enormous amount
of research has identified numerous protein factors as
putative hTERT regulators, the exact mechanisms involved
in the regulation of hTERT transcription are still far from
being fully established. It is likely that as yet unidentified
factors are important players in the control of activation
and repression of hTERT transcription.
In this context, Receptor Ck, a cell-surface receptor specific
for the cholesterol moiety in lipoprotein particles [13],
may be a good candidate for the regulation of hTERT tran-
scription. Receptor Ck has been shown to initiate a signal-
ing pathway that controls the expression of several genes
involved in cell cycle, such as, the genes encoding cyclin
D, Bcl-2, p27, c-myc and c-fos [14]. Out of these Receptor
Ck target genes, the c-myc and Bcl-2 gene products are
known modulators of hTERT transcription and telomer-
ase activity. Further, investigations have revealed that
Receptor Ck dependent signaling is defective in various
leukemic cell lines/patients and also in tumors of the cen-
tral nervous system [15,16]. The present study was thus,
designed to explore the effect, if any, of Receptor Ck
dependent signaling on hTERT transcription. We also
sought to identify the various transcription factors
involved in the above process. Besides the transcription
factors c-myc and Bcl-2, which were obvious candidates
for the potential link between Receptor Ck and hTERT
expression, we also examined cyclin D and peroxisome
proliferator-activated receptor γ (PPARγ). D-type cyclins
are rate-limiting controllers of G1 phase progression in
mammalian cells. Overexpression of these cyclins has
been detected in several types of cancers and an oncogenic
role for them has been suggested [17]. Chromosomal
translocations involving cyclin D1 locus have been
reported in different tumor types, such as, carcinoma of
the breast, oesophagus, stomach, bladder and liver, and in
squamous carcinomas of the head and neck [18]. PPARγ,
a ligand activated transcription factor of the nuclear hor-
mone receptor family, was initially characterized as a reg-
ulator of adipogenesis and glucose homeostasis [19]. New
investigations have revealed that PPARγ also regulates cell
proliferation/differentiation pathways and the expression
of many genes involved in carcinogenesis [19,20]. Given
their involvement in tumorigenesis, both cyclin D and
PPARγ are potential candidates for the regulation of
hTERT transcription.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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Time course of hTERT, c-myc and PPARγ mRNA expression in normal human PBMCs exposed to growth medium enriched  with 10% NHS Figure 1
Time course of hTERT, c-myc and PPARγ mRNA expression in normal human PBMCs exposed to growth 
medium enriched with 10% NHS. The cells were harvested at indicated time points (h-hours) and subjected to RNA 
extraction followed by RT-PCR. (A) Representative agarose gel photographs showing ethidium bromide stained RT-PCR prod-
ucts of hTERT, c-myc, PPARγ and β2M genes. (B) The signal intensities of RT-PCR products shown in panel A were measured 
using SCION IMAGE analysis software. The relative levels of hTERT, c-myc and PPARγ mRNA expression in each lane were 
determined by normalizing their individual band intensity to β2M band intensity. The mRNA expression of each gene at 4, 8 and 
12 h is plotted as percentage of that in control cells (i.e. cells harvested at 0 h). Each data point in the graph represents mean ± 
standard deviation (SD) of three separate experiments.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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The mRNA expression of hTERT, c-myc and PPARγ genes in normal human PBMCs treated with growth medium containing  10% NHS along with antibody against Receptor Ck(Ab RCk) Figure 2
The mRNA expression of hTERT, c-myc and PPARγ genes in normal human PBMCs treated with growth 
medium containing 10% NHS along with antibody against Receptor Ck (Ab RCk). Total cellular RNA was extracted 
at indicated time points (h-hours) and analyzed by RT-PCR. (A) Representative agarose gel photographs showing ethidium bro-
mide stained RT-PCR products of hTERT, c-myc, PPARγ and β2M genes. (B) The signal intensities of these RT-PCR products 
were measured using SCION IMAGE analysis software. The mRNA expression was determined by normalizing the band inten-
sity of target mRNA (hTERT, c-myc and PPARγ) to β2M band intensity. Data are expressed as percentage of control (cells har-
vested at 0 h). Each data point in the graph represents mean ± SD of three independent experiments.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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The majority of studies have evaluated the regulation of
hTERT and telomerase in tumor models. There is a relative
paucity of information on this front in normal cells.
Hence, the cellular models employed in the present study
were the normal human peripheral blood mononuclear
cells (PBMCs), which are known to express hTERT and tel-
omerase in a highly regulated manner. Our results
revealed a novel mechanism for the regulation of hTERT
transcription controlled by cholesterol activated Receptor
Ck.
Results
Involvement of Receptor Ck in the transcription of hTERT, 
c-myc and PPARγ genes
In order to determine whether cholesterol-activated
Receptor Ck regulates the transcription of hTERT, c-myc
The expression of hTERT, c-myc, PPARγ, cyclin D and bcl-2 genes over 12 h (hours) in normal human PBMCs treated with  growth medium containing 10% NHS and 2.5 mM EGTA Figure 3
The expression of hTERT, c-myc, PPARγ, cyclin D and bcl-2 genes over 12 h (hours) in normal human PBMCs 
treated with growth medium containing 10% NHS and 2.5 mM EGTA. The cells were harvested at indicated time 
points and subjected to RT-PCR and western blotting. (A) Representative agarose gel photographs showing ethidium bromide 
stained RT-PCR products of hTERT, c-myc, PPARγ and β2M genes. (B) Graph showing the changes in mRNA levels of hTERT, 
c-myc and PPARγ genes with increasing time after EGTA treatment. The relative levels of hTERT, c-myc and PPARγ mRNA 
expression were determined by measuring their band intensities using SCION IMAGE analysis software and normalizing to 
β2M band intensity. Data are expressed as percentage of control (0 h). Each data point represents mean ± SD of three inde-
pendent experiments. (C) Western blot analysis of expression of cyclin D and bcl-2 proteins. Equal amount of protein was 
used for the four samples. The western blot shown is a representative of three independent experiments.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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The hTERT, c-myc and PPARγ mRNA levels over 12 h (hours) in normal human PBMCs exposed to growth medium containing  10% NHS along with antibody against receptor Ck (Ab RCk) and 25-hydroxycholesterol (25OH-C; 1 µM) Figure 4
The hTERT, c-myc and PPARγ mRNA levels over 12 h (hours) in normal human PBMCs exposed to growth 
medium containing 10% NHS along with antibody against receptor Ck (Ab RCk) and 25-hydroxycholesterol 
(25OH-C; 1 µM). Total cellular RNA was extracted at indicated time points and amplified by RT- PCR. (A) Representative 
agarose gel photographs showing ethidium bromide stained RT-PCR products of hTERT, c-myc, PPARγ and β2M genes. (B) The 
signal intensities of these RT-PCR products were measured using SCION IMAGE analysis software. The relative levels of 
hTERT, c-myc and PPARγ mRNA expression were determined by normalizing their individual band intensity to β2M band 
intensity. The mRNA expression of each gene at 4, 8 and 12 h is plotted as percentage of that in control cells (cells harvested 
at 0 h). Each data point represents mean ± SD for the combined results of three separate experiments.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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and PPARγ genes in normal human PBMCs, the cells were
cultured in growth medium enriched with 10% normal
human serum (NHS) in the presence and absence of a
polyclonal monospecific antibody against Receptor Ck.
These cells were harvested at various time points and the
cellular mRNA levels of hTERT, c-myc and PPARγ genes
were measured by RT-PCR. In the cells exposed to growth
medium containing 10% NHS alone, Receptor Ck was
activated by the cholesterol moiety of low density lipopro-
tein (LDL) supplied by 10% NHS and a decrease in the
mRNA levels of hTERT, c-myc and PPARγ genes over 12
hours was observed (Figure 1). This decrease was abol-
ished in the presence of the antibody against Receptor Ck,
which blocked Receptor Ck activation. As shown in Figure
2, addition of antibody against Receptor Ck resulted in the
upregulation of mRNA expression of hTERT, c-myc and
PPARγ genes. Taken together, these results indicate that
Receptor Ck dependent signaling regulates the transcrip-
tion of hTERT, c-myc and PPARγ genes.
Since two receptors for LDL, namely apolipoprotein B
specific 'low density lipoprotein receptor (LDLR)' and
LDL-cholesterol specific 'Receptor Ck' are present on cells,
we wanted to confirm that the observed effect on the tran-
scription of hTERT, c-myc and PPARγ genes was not due
to LDLR. The possible involvement of LDLR was ruled out
by culturing normal human PBMCs in growth medium
enriched with 10% NHS in the presence of 2.5 mM ethyl-
eneglycol-bis-(β-aminoethylether)-N,N,N',N' -tetraacetic
acid (EGTA). EGTA is a known blocker of the interaction
of LDL with LDLR [21]. Hence, in the presence of EGTA,
LDLR pathway is shut off while Receptor Ck signaling is
functional. The results obtained after EGTA addition (Fig-
ure 3A &3B) were similar to those observed when PBMCs
were exposed to growth medium enriched with 10% NHS
without EGTA (Figure 1) thereby showing that the block-
age of LDLR pathway had no effect upon the transcription
of these genes. Hence, the cholesterol specific Receptor Ck
and not LDLR was responsible for the transcriptional reg-
ulation of hTERT, c-myc and PPARγ genes.
Role of Bcl-2 and cyclin D in Receptor Ck dependent 
regulation of hTERT gene transcription
Keeping in view the established link among Receptor Ck,
Bcl-2 and cyclin D [22], it was reasonable to speculate that
cyclin D and Bcl-2 could mediate the effect of Receptor Ck
on hTERT gene transcription. However, on comparing the
expression pattern of cyclin D and Bcl-2 proteins (Figure
3C) with the hTERT mRNA expression in human normal
PBMCs exposed to growth medium containing 10% NHS
and 2.5 mM EGTA (Figure 3B), no correlation was found
between cyclin D expression and hTERT transcription or
between Bcl-2 expression and hTERT transcription. While
cyclin D protein was expressed at only 4 hours and Bcl-2
protein was not expressed at all (Figure 3C), the level of
hTERT mRNA gradually decreased over 12 hours (Figure
3B). Hence, it was inferred that cyclin D and Bcl-2 might
not play any role in the regulation of hTERT transcription
in normal human PBMCs.
Role of c-myc in Receptor Ck dependent regulation of 
hTERT gene transcription
Substantial data have implicated c-myc in the upregula-
tion of hTERT transcription [7]. In order to determine
whether or not c-myc mediates the Receptor Ck dependent
down-regulation of hTERT gene transcription, normal
human PBMCs cultured in medium containing 10% NHS
were exposed to antibody against Receptor Ck along with
1 µM of 25-hydroxycholesterol (25OH-C), which is a neg-
ative regulator of c-myc mRNA and protein expression
[23]. As expected, c-myc mRNA levels declined gradually
over 12 hours due to the presence of 25OH-C (Figure 4).
A similar decrease was observed in hTERT mRNA expres-
sion (Figure 4), thus proving that Receptor Ck regulates
hTERT gene transcription indirectly by controlling the
transcription of c-myc gene. The PPARγ mRNA levels were
not affected by the addition of 25OH-C. In both the cases
– PBMCs exposed only to antibody against Receptor Ck
(Figure 2) and PBMCs exposed to antibody against Recep-
tor Ck along with 25OH-C (Figure 4) – the PPARγ tran-
script levels increased over 12 hours, demonstrating the
high specificity of the inhibitory effect of 25OH-C on c-
myc mRNA expression.
Effect of 25OH-C on the Receptor Ck dependent 
transcriptional regulation of hTERT, c-myc and PPARγ 
genes
As a control, the effect of 25OH-C was also investigated in
PBMCs cultured in the absence of antibody against Recep-
tor Ck. The exposure of PBMCs to growth medium con-
taining 10% NHS had resulted in a gradual decrease in the
mRNA levels of c-myc, PPARγ and hTERT genes over 12
hours (Figure 1). Due to the negative regulation of the c-
myc mRNA expression by 25OH-C, the addition of
25OH-C to this culture system was expected to further
decrease c-myc and hTERT mRNA levels while not affect-
ing the decline of PPARγ mRNA levels. However, surpris-
ingly, the exposure of normal human PBMCs to growth
medium containing 10% NHS along with 1 µM 25OH-C
revealed a completely different scenario (Figure 5). Addi-
tion of 25OH-C transiently abolished the Receptor Ck
dependent transcriptional down-regulation of hTERT, c-
myc and PPARγ genes observed in PBMCs cultured in
growth medium containing 10% NHS alone (Figure 1)
and exhibited a biphasic effect on the transcription of
these genes (Figure 5). The hTERT transcript levels
increased by about 9.3 fold as compared to the levels in
control cells after 4 hours of 25OH-C treatment (Figure
5). These levels then decreased to the hTERT mRNA levels
in control cells, at 8 hours and again increased slightlyBMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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RT-PCR analysis of expression of hTERT, c-myc and PPARγ mRNA in normal human PBMCs treated with growth medium con- taining 10% NHS and 25-hydroxycholesterol (25OH-C; 1 µM) for 0–12 h (hours) Figure 5
RT-PCR analysis of expression of hTERT, c-myc and PPARγ mRNA in normal human PBMCs treated with 
growth medium containing 10% NHS and 25-hydroxycholesterol (25OH-C; 1 µM) for 0–12 h (hours). (A) Repre-
sentative agarose gel photographs showing ethidium bromide stained RT-PCR products of hTERT, c-myc, PPARγ and β2M 
genes. (B) Graph showing the changes in mRNA levels of hTERT, c-myc and PPARγ genes with increasing time, after 25OH-C 
treatment. The relative levels of hTERT, c-myc and PPARγ mRNA expression were determined by measuring their band inten-
sities using SCION IMAGE analysis software and normalizing to β2M band intensity. Data are expressed as percentage of con-
trol (0 h). Each data point represents mean ± SD of three independent experiments.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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Effect of pioglitazone (PIO) on the mRNA expression of hTERT, c-myc and PPARγ genes Figure 6
Effect of pioglitazone (PIO) on the mRNA expression of hTERT, c-myc and PPARγ genes. The normal human 
PBMCs were treated with the indicated concentrations of pioglitazone and with vehicle (DMSO) alone (0 µM pioglitazone, 
control) for 24 hours. Total cellular RNA was extracted from harvested cells and subjected to RT-PCR analysis. (A) Repre-
sentative agarose gel photographs showing ethidium bromide stained RT-PCR products of hTERT, c-myc, PPARγ and β2M 
genes. (B) The signal intensities of RT-PCR products shown in panel A were measured using SCION IMAGE analysis software. 
The relative levels of hTERT, c-myc and PPARγ mRNA expression were determined by the ratio of their individual band inten-
sity to β2M band intensity. The mRNA levels are plotted as percentage of those in control cells. Each data point in the graph 
represents mean ± SD of three separate experiments.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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Effect of PPARγ silencing on hTERT gene transcription Figure 7
Effect of PPARγ silencing on hTERT gene transcription. Normal human PBMCs were transfected with scrambled 
siRNA (control scram siRNA) or with siRNA targeting PPARγ mRNA (PPARγ siRNA). These cells were cultured for 72 hours 
and then subjected to RNA extraction and RT-PCR analysis. (A) Representative agarose gel photographs showing ethidium 
bromide stained RT-PCR products of PPARγ, hTERT and β2M genes. (B) The signal intensities of RT-PCR products were meas-
ured using SCION IMAGE analysis software. The mRNA expression was determined by normalizing the band intensity of tar-
get mRNA (hTERT and PPARγ) to β2M band intensity. The hTERT and PPARγ mRNA levels in cells transfected with PPARγ 
siRNA are expressed as percentage of that in control (scram siRNA) cells. Each bar represents mean ± SD of experiments 
done in triplicate.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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Time course of hTERT, c-myc and PPARγ mRNA expression after treatment of normal human PBMCs with growth medium  containing 10% NHS and PMA (100 nM) Figure 8
Time course of hTERT, c-myc and PPARγ mRNA expression after treatment of normal human PBMCs with 
growth medium containing 10% NHS and PMA (100 nM). Total cellular RNA was extracted at indicated time points (h-
hours) and analyzed by RT-PCR. (A) Representative agarose gel photographs showing ethidium bromide stained RT-PCR prod-
ucts of hTERT, c-myc, PPARγ and β2M genes. (B) The signal intensities of these RT-PCR products were quantified using SCION 
IMAGE analysis software. The relative levels of hTERT, c-myc and PPARγ mRNA expression were obtained by the ratio of 
their individual band intensity to β2M band intensity. The normalized mRNA expression of each gene at 4, 8 and 12 h is plotted 
as percentage of that in control cells (0 h). Each data point in the graph represents mean ± SD of three separate experiments.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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RT-PCR analysis of expression of hTERT, c-myc and PPARγ mRNA in normal human PBMCs exposed to growth medium con- taining 10% NHS along with antibody against receptor Ck (Ab RCk) and propranolol (PROP; 200 µM) for 0, 4 and 8 h (hours) Figure 9
RT-PCR analysis of expression of hTERT, c-myc and PPARγ mRNA in normal human PBMCs exposed to 
growth medium containing 10% NHS along with antibody against receptor Ck (Ab RCk) and propranolol 
(PROP; 200 µM) for 0, 4 and 8 h (hours). (A) Representative agarose gel photographs showing ethidium bromide stained 
RT-PCR products of hTERT, c-myc, PPARγ and β2M genes. (B) The signal intensities of RT-PCR products were measured using 
SCION IMAGE analysis software and the mRNA expression was determined by normalizing the band intensity of target mRNA 
(hTERT, c-myc and PPARγ) to β2M band intensity. The normalized mRNA expression of each gene is expressed as percentage 
of that in control (0 h) cells. Each data point represents mean ± SD of three independent experiments.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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(about 1.7 fold) at 12 hours (Figure 5). The c-myc and
PPARγ mRNA expression also followed a similar pattern
of time-dependent increase and decrease though the fold
increase was less as compared to that seen in hTERT
mRNA expression (Figure 5). The observation that the
addition of 25OH-C to PBMCs cultured in medium
enriched with 10% NHS is able to disrupt the Receptor Ck
dependent down-regulation of hTERT, c-myc and PPARγ
mRNA expression (Figures 1 &5) indicates that 25OH-C
also contributes to the transcriptional regulation of these
genes in normal human PBMCs. More importantly, the
data suggest the possibility that the presence of an oxys-
terol along with LDL could influence and alter the tran-
scriptional regulation of hTERT, c-myc and PPARγ genes
by LDL-cholesterol activated Receptor Ck.
Link between PPARγ activation and hTERT gene 
transcription
To evaluate the effect of PPARγ activation on the transcrip-
tion of hTERT, c-myc and PPARγ genes, the normal
human PBMCs were treated with different concentrations
(0–50  µM) of pioglitazone, a PPARγ agonist [24] and
mRNA expression of hTERT, c-myc and PPARγ genes was
determined by RT-PCR after 24 hours of pioglitazone
treatment. PPARγ mRNA levels remained largely
unchanged with increasing concentrations of pioglitazone
(Figure 6), showing that the agonist had no effect on
PPARγ gene transcription. On the other hand, c-myc and
hTERT mRNA expression exhibited a dose-dependent
decrease (Figure 6), thus implicating the transcription fac-
tor, PPARγ in the regulation of the transcription of c-myc
and hTERT genes.
To further verify the link between PPARγ and hTERT gene
transcription, we used PPARγ gene-specific small interfer-
ing RNA (siRNA) to knock down PPARγ mRNA expression
in normal human PBMCs and determined the effect of
PPARγ silencing on hTERT gene transcription. hTERT
mRNA expression was found to increase in PPARγ knock-
out cells as compared to that in control cells (Figure 7),
thereby indicating the role of PPARγ as a negative regula-
tor of hTERT transcription.
Role of PKC in Receptor Ck dependent signaling
Since previous studies have shown that Receptor Ck activa-
tion leads to the generation of the second messenger,
phosphatidic acid (PA) [22] and since PA can be dephos-
phorylated by the enzyme phosphatidic acid phosphohy-
drolase (PAP) to give rise to diacylglycerol (DAG), which
is an endogenous activator of protein kinase C (PKC)
[25,26], we hypothesized that PA, DAG and PKC may be
involved in the Receptor Ck dependent transcriptional reg-
ulation of c-myc, PPARγ and hTERT genes. In order to
assess the involvement of PKC in the Receptor Ck depend-
ent regulation of the transcription of hTERT, c-myc and
PPARγ genes, the normal human PBMCs were cultured in
growth medium enriched with 10% NHS in the presence
of 100 nM of phorbol 12-myristate 13-acetate (PMA),
which is a known activator of PKC [27,28]. The addition
of PMA abolished the decrease in hTERT, c-myc and
PPARγ mRNA expression that was observed in normal
human PBMCs cultured in medium enriched with 10%
NHS alone (Figures 1 &8). The exposure of PBMCs to
PMA resulted in a gradual increase in mRNA levels of
hTERT, c-myc and PPARγ genes over 12 hours (Figure 8).
The observation that PKC activation by PMA is able to
reverse the Receptor Ck dependent transcriptional down-
regulation of hTERT, c-myc and PPARγ genes suggests that
activated Receptor Ck down-regulates the transcription of
these genes by inhibiting PKC activation. Hence, PKC was
implicated in the Receptor Ck signaling pathway control-
ling the transcription of c-myc, PPARγ and hTERT genes.
To further verify the involvement of PKC in the Receptor
Ck signaling pathway, the effect of PKC inhibitor was
investigated in a situation where Receptor Ck activation
was blocked. The normal human PBMCs were cultured in
growth medium enriched with 10% NHS in the presence
of antibody against Receptor Ck and 200 µM of pro-
pranolol. Propranolol is known to be an inhibitor of the
enzyme phosphatidic acid phosphohydrolase (PAP),
which catalyses the conversion of PA to DAG [29]. Hence,
propranolol indirectly inhibits PKC by blocking the gen-
eration of its activator, DAG from PA. The addition of pro-
pranolol abrogated the increase in mRNA expression of c-
myc, PPARγ and hTERT genes that was observed in PBMCs
exposed to growth medium containing 10% NHS and
antibody against Receptor Ck  (Figures 2 &9). In the
PBMCs exposed to antibody against Receptor Ck along
with propranolol, the levels of c-myc, PPARγ and hTERT
mRNA slightly decreased over 8 hours (Figure 9). This
observation suggests that the upregulation of the tran-
scription of c-myc, PPARγ and hTERT genes in PBMCs
exposed to antibody against Receptor Ck alone was due to
PKC activation because the upregulation was abolished by
PKC inhibition brought about by the addition of pro-
pranolol. Hence, these data support the notion that the
down-regulation of the transcription of c-myc, PPARγ and
hTERT genes by activated Receptor Ck (Figure 1) involves
PKC inhibition while the upregulation of the transcrip-
tion of these genes observed during the blockage of Recep-
tor Ck activation (Figure 2) involves the activation of PKC.
Contribution of PKC to the 25OH-C mediated biphasic 
effect on the transcription of hTERT, c-myc and PPARγ 
genes
We also investigated the involvement of PKC in 25OH-C
mediated transcriptional regulation of c-myc, PPARγ and
hTERT genes. For this, normal human PBMCs were cul-
tured in growth medium containing 10% NHS and 1 µMBMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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The mRNA expression of hTERT, c-myc and PPARγ genes in normal human PBMCs treated with growth medium containing  10% NHS and 25-hydroxycholesterol (25OH-C; 1 µM) along with propranolol (PROP; 200 µM) Figure 10
The mRNA expression of hTERT, c-myc and PPARγ genes in normal human PBMCs treated with growth 
medium containing 10% NHS and 25-hydroxycholesterol (25OH-C; 1 µM) along with propranolol (PROP; 200 
µM). Total cellular RNA was extracted at indicated time points (h-hours) and amplified by RT- PCR. (A) Representative agar-
ose gel photographs showing ethidium bromide stained RT-PCR products of hTERT, c-myc, PPARγ and β2M genes. (B) The 
normalized mRNA expression of hTERT, c-myc and PPARγ genes obtained after analysis with SCION IMAGE software is 
expressed as percentage of that in control (0 h) cells. Each data point represents mean ± SD of three independent experi-
ments.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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25OH-C along with 200 µM of propranolol. As depicted
in Figure 10, addition of propranolol completely abro-
gated the biphasic effect of 25OH-C on the mRNA expres-
sion of c-myc, PPARγ and hTERT genes that was observed
in PBMCs exposed to medium containing 10% NHS and
1 µM 25OH-C (Figure 5). Since the action of propranolol
involves the blocking of the conversion of PA to DAG
leading to PKC inhibition, the above observation suggests
that the 25OH-C mediated biphasic effect involves activa-
tion of PKC.
Discussion
The present study has identified novel players, namely,
cholesterol specific Receptor Ck, PPARγ and oxysterol
(25OH-C) in the transcriptional regulation of hTERT
gene. Based on the results of our experiments, we have
proposed a signaling pathway (Figure 11) that links
Receptor Ck with hTERT gene transcription through the
transcription factors, c-myc and PPARγ. Despite the ability
of activated Receptor Ck to generate the second messenger
PA as reported by previous studies, the experiments of this
Proposed Receptor Ck – dependent signaling pathway involved in hTERT gene regulation at the transcriptional level Figure 11
Proposed Receptor Ck – dependent signaling pathway involved in hTERT gene regulation at the transcriptional 
level. [LDL-low density lipoproteins; C-cholesterol moiety; RCk-Receptor Ck; PC-phosphatidylcholine; PLD-phospholipase D; 
PA-phosphatidic acid; DAGK-diacylglycerol kinase; PAP-phosphatidic acid phosphohydrolase; DAG-diacylglycerol; PKC-pro-
tein kinase C; PPARγ-peroxisome proliferator activated receptor γ; NF-κB-nuclear factor -κB; hTERT-human telomerase 
reverse transcriptase; T-transcription; LDLR-low density lipoprotein receptor; ApoB-apolipoprotein B; EGTA-ethyleneglycol-
bis-(β-aminoethylether)-N,N,N',N'-tetraacetic acid; AbRCk-antibody against Receptor Ck; 25OH-C -25hydroxycholesterol; 
PROP-propranolol; PMA-phorbol 12-myristate 13-acetate; PIO-pioglitazone]BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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study demonstrate that Receptor Ck is not able to activate
PKC. The data of the present study suggest that activated
Receptor Ck may be involved in the inhibition of PKC. To
explain this, it was speculated that Receptor Ck could
inhibit PKC by blocking the production of DAG either by
inhibiting the enzyme PAP, which catalyses the conver-
sion of PA to DAG or by activating the enzyme diacylglyc-
erol kinase (DAGK) which catalyses the conversion of
DAG back to PA. The inhibition of PAP by Receptor Ck
does not explain the time-dependent biphasic effect on
the transcription of c-myc, PPARγ and hTERT genes that
was observed when normal human PBMCs were exposed
to 25OH-C (Figure 5). However, all the results are com-
patible with the Receptor Ck dependent DAGK activation
model. Hence, we propose that activated Receptor Ck may
be inhibiting PKC by activating DAGK (Figure 11).
The findings of this study reveal, for the first time, a link
between cholesterol (through Receptor Ck) and transcrip-
tion of hTERT gene in normal human PBMCs. The LDL-
cholesterol dependent activation of Receptor Ck  was
found to down-regulate hTERT gene transcription by
down-regulating the transcription of c-myc gene through
PKC inhibition (Figure 11). The Receptor Ck dependent
down-regulation of hTERT transcription observed in nor-
mal human PBMCs may reflect a general mechanism for
the repression of hTERT and telomerase expression in nor-
mal somatic cells. It is attractive to suggest that the failure
of this Receptor Ck dependent repressive mechanism may
contribute to upregulation of hTERT transcription and
induction of telomerase activity in cancer cells. In this
context, it is interesting to note that Receptor Ck expres-
sion has been found to be lacking in several leukemic cell
lines / patients [15].
The treatment of cells with PMA (PKC activator) was
found to abolish the Receptor Ck dependent transcrip-
tional down-regulation of hTERT, PPARγ and c-myc genes
and result in time-dependent increase in the mRNA levels
of these genes (Figures 1 &8). On the other hand, PKC
inhibition by propranolol resulted in the down-regula-
tion of mRNA expression of these genes (Figure 9). The
upregulation of PPARγ mRNA and protein expression by
PKC activators and its down-regulation by PKC inhibitors
has been observed by other groups [28,30,31]. Also, the
upregulation of c-myc gene expression by activation of
PKC has been reported [32]. Several studies have sug-
gested the important role of PKC isoforms in the upregu-
lation of telomerase activity through the PKC-mediated
phosphorylation of hTERT protein [7]. However, the role
of PKC in the transcription of hTERT gene has not been
thoroughly investigated. Kim et al. [33] observed that PKC
inhibitors decreased telomerase activities by decreasing
the expression of full length hTERT transcripts in human
cervical cancers. Consistent with this, the results of the
present study also suggest the involvement of PKC inhibi-
tion in the down-regulation of hTERT gene transcription
and PKC activation in the upregulation of hTERT gene
transcription.
The activation of PPARγ by its agonist pioglitazone was
found to down-regulate the mRNA expression of c-myc
and hTERT genes in PBMCs (Figure 6). Also, hTERT
mRNA expression was upregulated in PBMCs in which
PPARγ mRNA expression was knocked down as compared
to that in control PBMCs (Figure 7). This is, to the best of
our knowledge, the first report of a link between PPARγ
activation and hTERT gene transcription. The inhibition
of c-myc mRNA expression by activated PPARγ has also
been reported by other groups. Activation of PPARγ by lig-
ands such as troglitazone and 15-deoxy-∆12,14 – prostag-
landin J2 has been shown to down-regulate c-myc mRNA
and protein expression in colon cancer cells and leukemic
cell lines [34,35]. Whether PPARγ downregulates hTERT
gene transcription through a c-myc dependent or c-myc
independent mechanism remains an open question. It
has been reported that PPARγ directly interacts with the
transcription factor Sp1 at the protein level leading to
inhibition of Sp1 and thereby, the transcriptional down-
regulation of Sp1 target genes [36,37]. Also, activated
PPARγ has been shown to antagonize the activity of the
pleiotropic transcription factor, nuclear factor kappa B
(NF – κB) thus inhibiting the transcription of NF-κB target
genes [38,39]. Both of these transcription factors (Sp1 and
NF-κB) have been found to positively regulate hTERT
transcription [7-9]. Hence, the effect of activated PPARγ
on hTERT mRNA expression may also be mediated by the
transcription factors Sp1 and NF-κB (Figure 11). The pos-
sibility of a direct effect of activated PPARγ on hTERT gene
transcription through a PPARγ specific binding site on
hTERT promoter remains to be explored.
The link between activated PPARγ and hTERT transcrip-
tion observed in this study suggests that PPARγ activation
may have important implications in the processes of car-
cinogenesis and ageing. Recent studies have implicated
PPARγ in the regulation of genes relevant to carcinogene-
sis [20]. Deficient expression of PPARγ can be a significant
risk factor for carcinogenesis, although in some cases,
PPARγ overexpression has been demonstrated to enhance
carcinogenesis [20]. Our finding that PPARγ negatively
regulates hTERT transcription suggests that deficient
expression of PPARγ may contribute to carcinogenesis
through the upregulation of hTERT expression. The link
between PPARγ and hTERT gene expression also assumes
importance in the light of the fact that PPARγ can be acti-
vated by a large number of ligands, which include polyun-
saturated fatty acids, metabolites of prostaglandin J,
antidiabetic drugs (thiazolidinediones) and a variety of
nonsteroidal anti-inflammatory drugs [40]. All these mol-BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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ecules may repress hTERT gene expression and thereby,
telomerase activity through PPARγ activation. It is inter-
esting to note here that ligand activation of PPARγ has
been shown to inhibit proliferation and induce apoptosis
in several cancer cells such as, breast, colon and prostate
cancer cells and in various leukemic cell lines [34,35].
Besides implicating cholesterol (through Receptor Ck) in
the transcriptional regulation of hTERT gene, the present
study reveals the involvement of oxysterols, the oxygen-
ated derivatives of cholesterol, in the regulation of hTERT
gene transcription. Initially used in the study as an inhib-
itor of c-myc mRNA expression, the oxysterol, 25OH-C
was found to have a dual effect on the expression of
hTERT gene. This dual effect was found to depend on the
activation / inactivation of Receptor Ck. When Receptor Ck
was not activated due to the presence of antibody against
Receptor Ck in the 'PBMCs + Medium + 10% NHS + 1 µM
25OH-C + Antibody against Receptor Ck' culture system,
25OH-C repressed hTERT mRNA levels by inhibiting c-
myc mRNA expression (Figure 4). In contrast, when
25OH-C was present along with activated Receptor Ck as
in 'PBMCs + Medium + 10% NHS + 1 µM 25OH-C' cul-
ture experiment (Figure 5), it abrogated the Receptor Ck
dependent down-regulation of hTERT, c-myc and PPARγ
mRNA expression and transiently upregulated the mRNA
levels of these genes (Figures 1 &5). A time-dependent
biphasic effect on the mRNA levels of hTERT, c-myc and
PPARγ genes was observed in this situation (Figure 5) sug-
gesting that 25OH-C might be interacting at some point
with the Receptor Ck signaling pathway, leading to the
transient upregulation of the genes under study. In an
attempt to understand the mechanism underlying the
observed biphasic effect of 25OH-C, we investigated the
effect of PKC inhibition on this action of 25OH-C. Inhibi-
tion of PKC by propranolol was found to abolish the
biphasic effect of 25OH-C (Figure 10) showing that the
25OH-C mediated transient disruption of Receptor Ck
dependent signaling involved the conversion of PA to
DAG and PKC activation. This observation coupled with
the previous report that 25OH-C possesses the ability to
amplify the Receptor Ck dependent generation of PA [42]
suggests that PA generation followed by the conversion of
PA to DAG and PKC activation may be the point at which
25OH-C interacts with Receptor Ck dependent signaling
pathway. Due to the increase in the generation of PA
when 25OH-C is present along with activated Receptor
Ck, PKC could be activated (even in the presence of acti-
vated Receptor Ck) (Figure 11), leading to the observed
transient upregulation of the mRNA expression of c-myc,
PPARγ and hTERT genes (Figure 5). Decrease in the mRNA
levels of these genes, observed during the biphasic effect is
due to the Receptor Ck dependent DAGK activation result-
ing in the inhibition of PKC (Figures 5 &11). Hence, the
biphasic effect on the mRNA expression of c-myc, PPARγ
and hTERT genes observed when 25OH-C is present along
with activated Receptor Ck is attributed to the ability of
25OH-C to activate PKC and the ability of activated
Receptor Ck to inhibit PKC (Figures 5 &11). These obser-
vations, which suggest a role for the oxygenated derivative
of cholesterol in the regulation of hTERT gene transcrip-
tion and more importantly, reveal the ability of 25OH-C
to reverse the Receptor Ck  dependent transcriptional
repression of hTERT, c-myc and PPARγ genes may have
important implications given the diverse biological roles
of oxysterols. It is pertinent to note here that 25OH-C is
one of the abundant oxysterols present in the human
plasma [43,44]. The oxysterols have been implicated in a
variety of cellular processes including lipid metabolism,
apoptosis and cell differentiation [43]. Several studies
have indicated that oxysterols play an important role in
the development of atherosclerosis [43]. Oxysterols have
also been suggested as potential cancer chemotherapeutic
agents [43].
The peripheral blood immune cells exhibit particularly
interesting telomere dynamics. Despite the presence of
telomerase, the telomeres in these cells shorten progres-
sively with increasing age and with cellular replication in
vitro [45,46]. Telomere attrition even in the presence of
telomerase suggests that the level of hTERT and telomer-
ase expression is insufficient for the maintenance of tel-
omere lengths. This deficient expression of hTERT and
telomerase in PBMCs possibly represents a tumor sup-
pressor mechanism, essential for the protection of these
cells against the development of cancer. The Receptor Ck-
dependent down-regulation of hTERT mRNA expression
observed in the present study may cooperate with the
other repressive mechanisms operational in PBMCs in
order to maintain appropriate low levels of telomerase in
these cells. Further, it has been reported that unlike most
telomerase positive cells, peripheral blood lymphocytes
do not exhibit a tight correlation between hTERT mRNA
expression and telomerase activity. The hTERT transcripts
are expressed in these cells independently of the presence,
absence or quantitative level of detectable telomerase
activity [47]. However, hTERT transcription is upregulated
along with the increase in telomerase activity during the
activation of peripheral blood cells. [47]. In the present
study, since Receptor Ck activation has been found to
down-regulate hTERT transcription, it is expected to
repress telomerase activity as well, because the enzymatic
activity of telomerase can not possibly occur in the
absence of hTERT, the catalytic subunit of telomerase. The
absence of correlation between hTERT mRNA expression
and telomerase activity in PBMCs suggests that hTERT
may have some other roles besides contributing to telom-
erase activity and telomere lengthening. Recent studies
have, indeed, shown that actions of hTERT in cellular pro-
liferation and tumor progression extend beyond the sin-BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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gular role of telomere maintenance [48]. hTERT has also
been shown to enhance cell survival independent of its
effect on telomere length maintenance [48]. Hence, the
study of hTERT transcription irrespective of its contribu-
tion to telomerase activity assumes importance. Besides
participating in the suppression of telomerase, Receptor
Ck dependent down-regulation of hTERT transcription
may be involved in the other as yet uncharacterized roles
of hTERT in PBMCs.
Conclusion
The findings of this study provide new insights into the
regulation of hTERT transcription and may have impor-
tant implications in cancer and ageing research.
Methods
Materials
Lipoprotein deficient serum (LPDS), fetal bovine serum
(FBS), Ethyleneglycol-bis-(β-aminoethylether)-N,N,N',N'
-tetraacetic acid (EGTA), 25-Hydroxycholesterol (25OH-
C), Phorbol 12-myristate 13-acetate (PMA) and DL-Pro-
pranolol hydrochloride were purchased from Sigma
(U.S.A.). Pioglitazone was kindly provided by Dr. S.
Varma (Department of Internal Medicine, Postgraduate
Institute of Medical Education & Research, Chandigarh,
India). Specific antibodies against cyclin D and Bcl-2 were
obtained from Santa Cruz Biotechnology, Inc. (U.S.A.).
Polyclonal monospecific antibody against Receptor Ck
was raised in our laboratory as reported earlier [49]. All
the other reagents used in the study were of the highest
quality commercially available.
Cell culture and treatments
Normal human peripheral blood mononuclear cells
(PBMCs) were obtained from healthy volunteers, who
were fasting for 12 hours and abstained from any medica-
tion for 2 weeks before blood donation. Blood was drawn
through venipuncture into heparinized tubes and PBMCs
were isolated using Ficoll-Hypaque gradient centrifuga-
tion [50]. These PBMCs were washed twice with phos-
phate buffered saline and then cultured at a density of 0.5
× 106 cells/ml in Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% LPDS, 2 mM L-
glutamine, 20 mM HEPES (N-2-hydroxyethyl piperazine-
N' -2-ethanesulphonic acid), 24 mM sodium bicarbonate,
50 units/ml penicillin and 50 µg/ml streptomycin. Cultur-
ing was done for 24 hours at 37°C in humidified 5% CO2
atmosphere. At the end of this incubation period, the
PBMCs were exposed to fresh DMEM containing 10%
heat-inactivated normal human serum (NHS) in place of
LPDS. At this stage, PBMCs were cultured for an addi-
tional 0, 4, 8 and 12 hours either in the presence of
medium + 10% NHS alone or in combination with anti-
body against Receptor Ck, EGTA (2.5 mM), 25OH-C (1
µM), PMA (100 nM) or propranolol (200 µM). Cells were
harvested by centrifugation at 250 × g for 15 minutes and
the obtained pellets were subjected to RNA and protein
extraction.
To study the effect of PPARγ activation, PBMCs cultured in
DMEM containing 10% FBS were used instead of LPDS
treated PBMCs. These cells were preincubated with differ-
ent concentrations (0–50 µM) of pioglitazone (a synthetic
PPARγ agonist belonging to the class of thiazolidinedione
antidiabetic agents) in FBS-free medium for 4 hours. After
4 hours, 10% FBS was added and the cells were harvested
after culturing for additional 20 hours. Harvested cells
were subjected to RNA isolation.
Both propranolol and pioglitazone were prepared fresh
before use by dissolving in dimethyl sulfoxide (DMSO).
Stocks of PMA and 25OH-C were made by dissolving in
DMSO and absolute ethanol respectively. These stock
preparations were stored at -20°C and diluted immedi-
ately before use. Vehicle concentration in the medium was
maintained at 0.1% vol/vol. Viable cells always exceeded
90% as determined by trypan blue exclusion dye test.
RNA extraction
Total cellular RNA was extracted by the acid guanidinium
phenol chloroform method [51]. RNA yield and purity
were determined spectrophotometrically at 260–280 nm
and the integrity of RNA verified by electrophoresis
through denaturing agarose gels stained with ethidium
bromide.
Determination of c-myc, hTERT and PPARγ mRNA 
expression by reverse transcriptase-polymerase chain 
reaction (RT-PCR)
First strand cDNA was synthesized from total extracted
RNA using the RevertAid™ first strand cDNA synthesis kit
from Fermentas. The cDNA was then amplified using
primers specific for c-myc, hTERT, PPARγ and β2
microglobulin (β2M) under the conditions described else-
where [52-55]. PCR was performed using 24, 36, 24 and
17 cycles for c-myc, hTERT, PPARγ and β2M amplification
respectively. The number of cycles was determined in pre-
liminary experiments to be within the exponential range
of PCR amplification. β2M expression was used as a con-
trol for RNA loading and efficiency of reverse transcrip-
tion.
PCR products were resolved on 2% agarose gels stained
with ethidium bromide. The gels were visualized in ultra-
violet light and photographed. Band intensities were eval-
uated using the SCION IMAGE analysis software. The
relative levels of c-myc, hTERT and PPARγ mRNA expres-
sion were obtained by the ratio of their individual band
intensity to β2M band intensity.BMC Cell Biology 2006, 7:2 http://www.biomedcentral.com/1471-2121/7/2
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Determination of cyclin D and Bcl-2 expression by western 
blotting
Equal amounts of proteins per sample were separated on
12.5% sodium dodecyl sulphate – polyacrylamide gels
and then electro-transferred to nitrocellulose membranes.
The membranes were probed using specific antibodies
against cyclin D and Bcl-2.
Silencing of PPARγ gene using small interfering RNA 
(siRNA)
Total cellular RNA was extracted from normal human
PBMCs and subjected to RT-PCR using primers specific for
PPARγ [52]. This PCR product was employed as a tem-
plate for the production of double stranded RNA (dsRNA)
using the BLOCK-iT™ RNAi TOPO Transcription kit (Inv-
itrogen). The dsRNA was diced into PPARγ gene-specific
siRNA using the BLOCK-iT™ Dicer RNAi kit (Invitrogen).
Scrambled siRNA was used as a negative control. PPARγ-
specific siRNA or scrambled siRNA were transfected into
normal human PBMCs using the Lipofectamine™ 2000
reagent (Invitrogen). These cells were harvested after 72
hours and subjected to RNA extraction and RT-PCR anal-
ysis in order to determine the relative levels of PPARγ and
hTERT mRNA expression.
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